fda compounding semaglutide news today 2025 Intensifies Crackdown on GLP-1 compounded semaglutide crackdown news october

Its triple receptor mechanism means it changes glucose regulation, gastric motility, and body weight in ways that ripple through how other medications work

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from dual agonists such as tirzepatide and single agonists such as semaglutide

Always consult your prescriber before changing your dose

LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025

These companies currently offer five GLP-1 drugs approved for type 2 diabetes, with four also approved for various cardiovascular conditions

Choose semaglutide for a holistic approach to weight loss and health improvement, supported by its proven efficacy and user-friendly administration